Medpace Holdings Inc is a global contract research organization (CRO) that specializes in providing a range of services to the pharmaceutical and biotechnology industries
The company supports clients throughout the drug development process, offering expertise in clinical trials, regulatory compliance, and data management. Medpace focuses on delivering efficient and high-quality clinical services across various therapeutic areas, helping to streamline the path from clinical research to market approval. Through its integrated approach, the company aims to accelerate the development of new treatments while ensuring adherence to safety and regulatory standards.
Medpace has been treading water for the past six months, recording a small loss of 4.4% while holding steady at $334.43. The stock also fell short of the S&P 500’s 7.6% gain during that period.
Shares of clinical research company Medpace Holdings (NASDAQMEDP)
fell 8.7% in the pre-market session after the company reported weak fourth-quarter results: Medpace's full-year revenue, EPS, and EBITDA guidance fell short of Wall Street's estimates. The weaker-than-expected outlook suggests slowing business momentum, as reflected in the declining book-to-bill ratio of 0.99x. On the other hand, the company exceeded analysts' EPS and EBITDA expectations this quarter.Overall, this quarter could have been better.
Clinical research company Medpace Holdings (NASDAQMEDP) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 7.7% year on year to $536.6 million. On the other hand, the company’s full-year revenue guidance of $2.16 billion at the midpoint came in 3.5% below analysts’ estimates. Its GAAP profit of $3.67 per share was 24.1% above analysts’ consensus estimates.
The regular session of the US market on Monday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its fourth quarter and fiscal year 2024 financial results after the market close on Monday, February 10, 2025. The Company will host a conference call the following morning, Tuesday, February 11, 2025, at 9:00 a.m. ET to discuss these results.
LOS ANGELES, CA / ACCESSWIRE / December 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQMEDP) for violations of the securities laws.
LOS ANGELES, CA / ACCESSWIRE / December 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQMEDP) for violations of the securities laws.
LOS ANGELES, CA / ACCESSWIRE / December 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQMEDP) for violations of the securities laws.
LOS ANGELES, CA / ACCESSWIRE / December 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQMEDP) for violations of the securities laws.
LOS ANGELES, CA / ACCESSWIRE / December 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQMEDP) for violations of the securities laws.
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Medpace Holdings, Inc. (“Medpace” or the “Company”) (NASDAQMEDP) on behalf of Medpace stockholders. Our investigation concerns whether Medpace has violated the federal securities laws and/or engaged in other unlawful business practices.
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Medpace Holdings, Inc. (“Medpace” or “the Company”) (NASDAQMEDP). Investors who purchased Medpace securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/MEDP.
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Medpace Holdings, Inc. (“Medpace” or “the Company”) (NASDAQMEDP). Investors who purchased Medpace securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/MEDP.
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Aviat Networks, Inc. (NASDAQAVNW), Medpace Holdings, Inc. NASDAQ: MEDPNASDAQMEDP)(NYSE: CUBINYSECUBI, and Ibotta, Inc. (NYSE: IBTANYSE). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. (“Medpace” or “the Company”) (NASDAQMEDP) for violations of the securities laws.
